#United States #Nashville #Stroke Treatment #Terumo Neuro #SOFIA™ 88

Terumo Neuro Unveils SOFIA™ 88 Catheter Performance Data

Terumo Neuro, a significant player in the field of neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, recently disclosed compelling new data on its SOFIA™ 88 Neurovascular Support Catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) Annual Meeting. This data, which is being presented for the first time, highlights its impressive performance metrics, particularly against a backdrop of competing super-bore catheters.

The SOFIA™ 88 catheter was evaluated through real-world U.S. physician preference data collected from 105 procedures at 37 medical centers and involving 41 physicians. Notably, the findings revealed that 95% of doctors confirmed that the SOFIA™ 88 catheter successfully reached its target location consistently—even in complex anatomical situations, with 59% of cases involving the internal carotid artery terminus (ICA-T) or even beyond.

Additionally, an impressive 86% of physicians expressed that they rated the SOFIA™ 88 catheter as "Better" or "Much Better" than other alternatives available on the market. Furthermore, it was found to outperform the ZOOM 88 catheter in 94% of the cases and the HiPoint 88 catheter in 79% of cases.

Carsten Schroeder, the President and CEO of Terumo Neuro, stated, "These real-world results further validate the SOFIA™ 88 catheter's position as a leading super-bore support catheter. This new dataset reinforces consistent feedback from physicians regarding the dependable performance of the SOFIA™ 88 catheter in critical situations. We take pride in seeing the catheter excel compared to other large-bore devices in real-world settings, a testament to our commitment to innovation and physician collaboration."

The SOFIA™ 88 Neurovascular Support Catheter was commercially launched in the U.S. on May 13, 2025, and represents a key addition to Terumo Neuro's expanding global portfolio for stroke treatment. Designed with reliability and adaptability in mind, the catheter offers advanced trackability, stability, and flexibility conducive to optimizing physician control and enhancing treatment efficacy across various aspiration and combination procedures.

Moreover, the physician preference data announced at the SNIS event complements previous findings from the SOFAST registry, which confirmed the safety and effectiveness of the SOFIA™ Flow Plus 6F catheter as a reliable frontline aspiration device. The SOFIA™ 88 catheter is also fully compatible with the SOFIA™ Flow Plus 6F Aspiration Catheter, representing a vital component within Terumo Neuro’s complete stroke treatment solution. This integrated solution includes:

• - ERIC™ Retrieval Device: Providing versatility and control over thrombus during procedures.
• - BOBBY™ Balloon Guide Catheter: Featuring next-generation balloon technology for effective flow arrest.
• - WEDGE™ and HEADWAY™ Microcatheters: Optimized for improved access and navigation support.
• - TRAXCESS™ Guidewires: Engineered for navigating through challenging anatomical structures.

In summary, Terumo Neuro is dedicated to creating innovative technologies that redefine neurovascular treatment paradigms with the aim of advancing physician capabilities and enhancing patient outcomes. Founded in 1997, Terumo Neuro has continued to expand its product offerings for cerebral aneurysms, ischemic strokes, carotid artery diseases, and various neurovascular conditions. Headquartered in California, the company distributes its products in over seventy countries via direct sales and strategic partnerships. For additional information, visit their website at www.terumoneuro.com.

Incorporating cutting-edge medical technology, Terumo Corporation, which has been operational for over a century, is committed to contributing to healthcare globally, employing more than 30,000 associates and providing innovative solutions in numerous healthcare domains across 160 countries.